Shots:The P-II (ALPACA) trial assessed lepodisiran (16, 96, or 400mg) vs PBO for ~18mos. in 320 pts, who were dosed at baseline & day 180, with an additional arm receiving 400mg at baseline & PBO at day 180; P-III [ACCLAIM-Lp(a)] trial enrollment is ongoingTrial met its 1EP, with 400mg reducing Lp(a) by 93.9%…
Aging is a natural part of life, but it doesn't mean giving up on good health and vitality. Many men worry about heart disease and other chronic diseases as they get older, but there are ways to tackle these concerns. Making small lifestyle changes can significantly improve men’s health as they age, leading to a…

